


Cutaneous malignancies



Gyorgy Paragh, MD, PhD, FAAD
Assistant professor
Department of Dermatology
Roswell Park Cancer Institute
Buffalo, NY, April 12, 2016

Disclosure

- Unless otherwise noted the pictures and tables were borrowed from:


VisualDx[®]

<http://www.visualdx.com>



DermNet NZ

<http://www.dermnetnz.org/>



Bologna: Dermatology, Third Edition
2012, Elsevier

Learning objectives

- Introduction to the skin
- Introduction to epidermal carcinogenesis
- Epidemiology of common cutaneous malignancies
- Classification of common cutaneous malignancies
- Treatment of common cutaneous malignancies

The skin is our largest organ

- Largest
- Most visible




Image: The Skin Man.
Copyright: Gunther von
Hagens: BODY WORLDS,
Institute for Plastination,
Heidelberg, Germany.
www.bodyworlds.com

Functions of the skin

- Maintaining internal homeostasis in light of variable external stimuli
 - Mechanical protection
 - Regulates temperature
 - Photoprotection
 - Barrier against micro-organisms
- Metabolic function (vitamin D)
- Detects sensory stimuli
- Excretion
- Esthetic, psychosocial role



Scanning electron micrograph of the epidermis.
<http://www.fishbase.org/abstract.asp?id=10444>




Light micrograph of the epidermis (H&E).
<http://www.fishbase.org/abstract.asp?id=10444>

Acute barrier deficiency SJS & TEN skin symptoms




Dermatol Ther. 2009 Sep;24(223):441-51.

The structure of the skin



The structure of the epidermis and epidermal cells

- Keratinocytes (85-90%)
- Melanocytes
- Langerhans cells
- Merkel cells
- Leukocytes




Keratinocyte differentiation tight regulation of function

barrier formation (lipid lamellae and corneocytes)


quick transformation

preparation for generation of the barrier interaction with transiently present cells

cell division, uptake of precursors, mechanical attachment to the dermis




Keratinocyte differentiation



Stratum basale

- AKA stratum germinativum
- Single layer of cuboidal/columnar cells
- Divided into stem cells and transit amplifying cells




Fuchs E J Cell Biol 2008;180:273-284

JCB

Stem cells

- Self renewing
- Slow rate of division
- Relative greater protection from accumulating mutations
- Division asymmetric: gives rise to transit amplifying cells and new stem cells



Biologics Dermatology, Third Edition, 2012, Elsevier

PROPERTIES OF STEM CELLS, TRANSIT AMPLIFYING CELLS AND TERMINALLY DIFFERENTIATED CELLS

	Stem cells	Transit amplifying cells
Self-renewal*	Unlimited	Limited
Potential for differentiation*	Multipotent	Limited
Cycling in normal epidermis	Slow ¹	Rapid
Proliferative potential (e.g. during fetal development and wound healing)	High	Limited ²
Growth in culture	Sustained clonal growth	Small abortive clones ³
Maintenance of tissue homeostasis	Yes	Limited

Biologics Dermatology, Third Edition, 2012, Elsevier

Stem cells

- Epidermal proliferative units

Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11830-5. Epub 2003 Aug 11.

Stem cells

- Keratinocyte stem cells reside in:
 - dermal papilla
 - hair bulge

Biologie: Dermatologie, Third Edition, 2012, Elsevier

Stratum spinosum

Spinosus Layer: bundles of K1/K10-keratin filaments, intercellular junctions rich in desmosomes AP2, C/EBP, Hes1, Notch 1/3

Basal Layer: sparse K5/K14-keratin filaments, intercellular junctions rich in adherens junctions p63, EGFR, IGFR, TjR11, Delta1

hemidesmosomes (α6β4), focal adhesions (α3β1)

laminin V, fibronectin, Col IV, TGfα, IGfβ

Fuchs E J Cell Biol 2008;180:273-284

© 2008 Rockefeller University Press **JCB**

Stratum granulosum

Granular Layer: tight junctions, lamellar granules, keratohyalin granules, keratin filament bundles, profilaggrin, loricrin, lipids

Spinosus Layer: bundles of K1/K10-keratin filaments, intercellular junctions rich in desmosomes AP2, C/EBP, Hes1, Notch 1/3

Basal Layer: sparse K5/K14-keratin filaments, intercellular junctions rich in adherens junctions p63, EGFR, IGFR, TjR11, Delta1

hemidesmosomes (α6β4), focal adhesions (α3β1)

laminin V, fibronectin, Col IV, TGfα, IGfβ

Fuchs E J Cell Biol 2008;180:273-284

© 2008 Rockefeller University Press **JCB**

Granular Layer

- Keratohyalin granules (profilaggrin, loricrin)**
 - responsible for visible granularity under light microscopy
- Lamellar granules**
 - AKA Lamellar bodies; membrane-coating granules, Odland bodies
 - Content: Mixture of lipids (phospholipids, sphingolipids and cholesterol) and mixture of hydrolytic enzymes (acid phosphatase, glycosidases, proteases and lipases)

Conrified envelope assembly begins in the granular cell layer (and upper stratum spinosum)

http://birdgenetics.au.ty

Lipid level changes during KC differentiation

	Basal Cells	Granular Cells	Stratum Corneum Cells
Phospholipid (PC, SPM)	~5	~5	~5
Glucosylceramide	~1	~5	~10
Ceramide	~1	~5	38 fmol
Cholesterol Ester	~1	~2	~10
Cholesterol Sulfate	~1	~2	~10
Cholesterol	~1	~5	39 fmol
Triacylglycerol	~1	~5	~10
Fatty Acids	~1	~5	48 fmol


Mass of lipid per cell in pg

Ceramide : Cholesterol : Fatty Acids molar ratio = 1 : 1 : 1


Liebish G. et al University of Regensburg (unpublished data)

Major lipid classes in the barrier

- Cholesterol
- Free fatty acids
- Ceramides



Stratum corneum




Fuchs E J Cell Biol 2008;180:273-284

© 2008 Rockefeller University Press

JCB

Basic structure and function of the stratum corneum



Lipid lamellae:

A continuous tightly packed lipid matrix

Composition:

sphingolipids
very long chain highly saturated fatty acids
cholesterol, cholesterol sulfate

Chemical protective interface

Corneocytes:

Protein scaffold of dead cells

Composition:

filaggrin, loricrin, involucrin ...

Mechanical protective role

Outline

- Non-melanoma skin cancer
 - Epidemiology
 - Risk factors
 - UV radiation
 - Photocarcinogenesis
 - Non-melanoma skin cancer
 - Basal cell carcinoma
 - Squamous cell carcinoma
- Melanoma
 - Melanocyte biology
 - Epidemiology
 - Melanoma subtypes
 - Therapy

Non-melanoma Skin Cancers

- Includes basal cell carcinomas (BCC) & squamous cell carcinomas (SCC)
- Most common malignancies in humans
- 5.4 million cases annually in the US, in 3.3 million patients
 - 20-25% of the US population is projected to develop NMSC during their life
 - 40-50 percent of Americans who live to age 65 will have either basal cell carcinoma or squamous cell carcinoma at least once
 - Worldwide in all races
- BCCs: 2,800,000 in US per year (~80%)
- SCCs: 700,000 in US per year (~20%)
- ~80% rise in incidence in the last 2 decades


<http://www.skincancer.org/skin-cancer-information/skin-cancer-facts>

Cancer statistics



FIGURE 1. Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2014. Estimates are rounded to the nearest 10 and rates include liver and gall bladder and skin cancers and all other common second primary cancers.

<http://seer.cancer.gov/2016/04/08/cancer-deaths-by-second-look/>



Non-melanoma Skin Cancers

- Total cost of NMSC approximately \$4.8 billion for the US healthcare system
 - Melanoma: \$3.3 billion
- Within 5 years, second NMSC diagnosed in 70% of men, 50% of women
- 2000-2500 deaths per year

http://www.skincancer.org/skin-cancer-information/skin-cancer-facts

Risk factors for development of NMSC

Environmental Exposures	SCC	BCC
Cumulative/occupational sun exposure	+	
Intermittent/recreational sun exposure		+
Other exposures to UV light (PUVA, tanning beds)	+	+
Ionizing radiation	+	+
Chemicals (Arsenic)	+	+
Human papillomavirus (HPV)	+	
Cigarette smoking	+	

Risk factors for development of NMSC

Genetic syndromes	SCC	BCC
Xeroderma pigmentosum	+	+
Oculocutaneous albinism	+	+
Epidermodysplasia verruciformis	+	
Muir-Torre syndrome	+	+
Nevoid basal cell carcinoma syndrome		+
Dystrophic epidermolysis bullosa	+	

Risk factors for development of NMSC

Predisposing clinical settings	SCC	BCC
Chronic non-healing wounds	+	
Long standing discoid lupus erythematosus	+	
Lichen planus (erosive) or lichen sclerosis	+	
Linear porokeratosis	+	

Risk factors for development of NMSC

Immunosuppression	SCC	BCC
Organ transplantation	+	+
Other (e.g. chronic lymphocytic leukemia treated with fludarabine, AIDS pts with HPV infection)	+	

Risk factors for development of NMSC

Pigmentary phenotype	SCC	BCC
Fair skin	+	+
Always burns, never tans	+	+
Freckling	+	+
Red hair	+	+



Image: <https://www.pinterest.com/pin/48526292859901188/>

The effects of UV radiation on the skin



Outline


- **Introduction**
(definition, physical properties, UV sources, depth of penetration into the skin, action spectrums)
- **Cellular effects of UVR**
(biomolecules effected by UV, DNA damage)
- **UVR induced skin changes**
(sunburn, tanning, epidermal hypreplasia, vitamin D production, emotional effects, photoaging, photoimmunology, **photocarcinogenesis**)

Outline

- **Introduction**
(definition, physical properties, UV sources, depth of penetration into the skin, action spectrums)
- **Cellular effects of UVR**
(biomolecules effected by UV, DNA damage)
- **UVR induced skin changes**
(sunburn, tanning, epidermal hypreplasia, vitamin D production, emotional effects, photoaging, photoimmunology, **photocarcinogenesis**)

The visible light and the UV spectrum

- UV radiation



<http://www.bentley.com/obscure/what-is-uv-light>

Relevant UV spectrum

- Dermatologically important UV categories:

UVA 315-400nm

UVA1 340-400nm

UVA2 315-340nm


UVB 290-315nm

UVC 200-290


!

What happens to the UV radiation reaching physical matter

- Reflection
- Scattering
- Transmission
- Absorption




Solar radiation spectrum



Atmospheric effects on solar UV radiation

Sunlight at the top of the atmosphere:
1366 W/m^2

- 50% infrared light (IR)
- 40% visible light (VL)
- 10% ultraviolet light (UVR) (137 W/m^2)



Sunlight at ground level:
1000-1100 W/m^2

- 53% IR
- 44% VL
- 3% UVR (Sun at zenith)

With Sun at zenith at ground level:
IR: 527 W/m^2 , VL: 445 W/m^2 , UVR 32 W/m^2


Artificial UV sources

- UV radiation
 - Artificial light sources
 - Germicidal light (UVC)
 - Welding arc (UVC-visible)
 - Short distance not sufficient for oxygen to absorb the light
 - Counterfeit money detectors (UVA); 380-395nm
 - Nail salon UV light
 - Other artificial sources:
 - tanning booths
 - black lights
 - curing lamps
 - mercury vapor lamps
 - halogen lights
 - high-intensity discharge lamps
 - fluorescent and incandescent sources
 - some types of lasers (excimer lasers, nitrogen lasers, and third harmonic Nd:YAG lasers).



UV spectrum of tanning beds

typically
99-97% UVA
1-3% UVB




Nail lamp UV spectrum

UV carcinogenic potential similar to 1 session of NBUBV*:

- 13000 sessions of Nail UV with devices A & B were needed
- 40000 sessions of Nail UV with device C

*15-30 treatments



UV radiation penetration into the skin

5% of UVR is reflected


UVB

Epidermal absorption:

- urocanic acid
- DNA / RNA
- Tryptophan
- Tyrosine
- Melanin


Dermal absorption:

- DNA/RNA
- Elastin
- Collagen



<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1669494/figure/fig1.html>

Erythema and DNA-damage action spectrum



<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1669494/figure/fig2.html>

The action spectrum of photocarcinogenesis.





Figure 2 An action spectrum for UV carcinogenesis. The curve shows the effectiveness of UV radiation for the induction of squamous cell carcinoma in *harpes absters mice*, as a function of wavelength. (From de Gruij and van der Leun.* With permission.)

Volume 25, Issue 14, December 2000, pages 2024-2030
Skin cancer and solar UV radiation
F. de Gruij

Erythema and DNA-damage action spectrum



<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1669494/figure/fig3.html>

Outline

• Introduction

(definition, physical properties, UV sources, depth of penetration into the skin, action spectrums)

• Cellular effects of UVR


(biomolecules effected by UV, DNA damage)

• UVR induced skin changes

(sunburn, tanning, epidermal hyperplasia, vitamin D production, emotional effects, photoaging, photoimmunology, photocarcinogenesis)


UV radiation targets in the skin

- Urocanic acid
- Tryptophan
- Tyrosine
- Melanin
- Elastin
- Collagen
- DNA / RNA




UV effects on DNA

- Pyrimidine dimers
- Covalent link induced by UV radiation between adjacent pyrimidine bases



UV effects on DNA

- cyclobutane pyrimidine dimers (CPD)
 - CPDs are the most common UV mutation
 - TT dimer is the most common CPD
 - The most common mutation is C-T
 - Base pairing cannot take place during DNA replication
- 6,4 pyrimidine-pyrimidones (6,4-photoproducts)
 - Occur less frequently (approx 1:3 of CPD frequency)
 - More efficiently removed from the genome
 - Much less mutagenic
 - Mutagenic conversions are not known



UV induced oxidative stress

- UV activates covalent double bond containing small molecules (riboflavin, tryptophan and porphyrin)
- These activate cellular oxygen
- Indirect DNA damage
- 8-hydroxyguanine (8OH-G)
- thymine glycol
- strand breaks

Science

Home News Journals Topics Careers
Science Science Advances Science Immunology Science Robotics Science Signaling Science Translational Medicine

SHARE

RESEARCH ARTICLE

Chemixcitation of melanin derivatives induces DNA photoproducts long after UV exposure

Sanjay Premi¹, Silvia Wallisch¹, Camila M. Mano^{1,2}, Adam B. Weiner^{1,3}, Antonella Bacchocchi¹, Kazumasa Wakamatsu⁴, Etevlino J. H. Bechara^{2,5,1}, Ruth Halaban^{6,1}, Thierry Douki^{7,1}, Douglas E. Brash^{1,8,1}

¹Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA

²Departamento de Química, Instituto de Química, Universidade de São Paulo, São Paulo 05512-970 SP, Brazil

³Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA

⁴Department of Chemistry, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-1192, Japan

⁵Departamento de Ciências Exatas e da Terra, Universidade Federal de São Paulo, Osasco, São Paulo 09972-270 SP, Brazil

⁶Radiation Oncology Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA

⁷INAC-CR/LMIR-ES/CEA-LSU/Commissariat à l'Énergie Atomique (CEA), IRS04 Grenoble Cedex 9, France

⁸Corresponding author. E-mail: douglas.brash@yale.edu


*† These authors contributed equally to this work.

† Present address: Professor School of Medicine, University of Chicago, Chicago, IL 60637, USA

Science 20 Feb 2015
10.1126/science.1264187
DOI: 10.1126/science.1264187


Chemixcitation of melanin derivatives induces DNA photoproducts long after UV exposure

Sanjay Premi¹, Silvia Wallisch¹, Camila M. Mano^{1,2}, Adam B. Weiner^{1,3}, Antonella Bacchocchi¹, Kazumasa Wakamatsu⁴, Etevlino J. H. Bechara^{2,5,1}, Ruth Halaban^{6,1}, Thierry Douki^{7,1}, Douglas E. Brash^{1,8,1}



Science, 2015, Feb 20;347(6224):842-7.

Nucleotide excision repair



Creative Commons Attribution 3.0 Generic license

Xeroderma pigmentosum

- Symptoms: Development of numerous lentigines at an early age



Xeroderma pigmentosum

Photosensitivity goes along with increased skin cancer incidence:

	XP	general population
median age of first NMSC:	9 yrs	67 yrs
median age of first melanoma:	22 yrs	55 yrs




(Kraemer et al. 1994; Bradford et al. 2011; DiGiovanna et al. 2012)

Repair is error prone

- Most common UV induced mutations

- C → T
- CC → TT




- UVB and daylight UV induce CPDs preferentially at 5-methylcytosine(mC)-containing dipyrimidine sites
- UV signature mutations occur frequently at the dipyrimidine sites associated with methylated CpG

Difference between UVA and UVB mutagenesis


- UVB: mostly direct DNA damage with limited secondary ROS effect
- UVA: 8-hydroxyguanine, CPDs (high amount compared to previously expected) no 6,4PPs or Dewar isomers

J. Biol. Chem. 283, 1323-1331 (2008) | doi:10.1074/jbc.M71474-2008 | The Mechanisms of UV Mutagenesis

DNA damage signaling



Jackson SP and Bartek J. (2009) The DNA damage response in human biology and disease. Nature 461, 329-338




Outline

- **Introduction**
(definition, physical properties, UV sources, depth of penetration into the skin, action spectrums)
- **Cellular effects of UVR**
(biomolecules effected by UV, DNA damage)
- **UVR induced skin changes**
(sunburn, tanning, epidermal hypreplasia, vitamin D production, emotional effects, photoaging, photoimmunology, **photocarcinogenesis**)


UVR induced skin changes

- sunburn
- tanning
- epidermal hypreplasia
- vitamin D production
- emotional effects
- photoaging
- photoimmunology
- photocarcinogenesis**




UV signature mutations

- The majority of the mutations are at dipyrimidine sites (T-T, C-C, C-T or T-C) and correspond to a C to T transition.
- More than 20% correspond to tandem mutations involving the two adjacent nucleotides of the dipyrimidine sites (C-C to T-T).



Sunburn cells

- Pyknotic nucleus
- Eosinophilic cytoplasm
- Keratin 5 +
- Lack of late differentiation markers
- Appear 6-24 hrs after UV exposure



medscape.com

↓
apoptotic keratinocytes


Photodermatol Photoimmunol Photomed. 1995 Aug;11(4):149-54

Sunburn cells

- Sunburn cells (SBC) are keratinocytes undergoing apoptosis
- protective mechanism against the carcinogenic, effects of ultraviolet-B irradiation
- Sunburn cell formation is critically regulated by signaling cascades arising from DNA damage, membrane receptor clustering and generation of reactive oxygen species
- The mitochondria act as major checkpoint, integrating upstream survival and pro- apoptotic pathways
- The final post-mitochondrial apoptotic phase is executed by caspases
- Deregulation of signaling cascades controlling SBC formation can ultimately lead to the development of skin cancer

The International Journal of Biochemistry & Cell Biology 37(2005) 1547-1553


Decision about cell fate



Z. Assefi et al. / Biochimica et Biophysica Acta 1755 (2005) 90 – 106

Importance of sunburn cell formation

- p53-deficient mice:
 - decreased sunburn cells production after UVB, develop more skin cancers
- GADD45 deficient mice
 - decreased sunburn cell production after UVB, develop more skin cancers




Altieri, L. D., & Sachs, T. (1995). The role of p53 in tumour suppression: Lessons from mouse models. Cell Mol Life Sci, 15, 48-61.
 Bruna, W., Chant, E., Altieri, L. D., Iwakuma, T., Hongre, M.,
 S.M. Sharma, R.S. et al. (2004). Increased sensitivity to UV irradiation in mice with a p53 point mutation. Cell Biol. 24, 888-896

Sunburn cell formation and erythema

- Multiple studies show that erythema and inflammatory response and sunburn cell production correlates
- Sub erythemogenic doses of UV radiation may still lead to small amount of sunburn cell formation


J Dermatol Sci. 2009 Jul;56(1):10-7. doi: 10.1016/j.jdermsci.2009.03.011. Epub 2009 May 2.
 J Drugs Dermatol. 2013 Apr;12(4):464-8.
 Journal of Investigative Dermatology (2004) 123, 783-787
 Kaidbey KH: The photoprotective potential of the new superpotent sunscreens. J Amer Acad Dermatol 23(3): 449-452, 1990.
 Ziegler A, Jonason AS, Leffell DJ, et al.: Sunburn and p53 in the onset of skin cancer. Nature 372(6508):773-776, 1994

Sunburn cells



- Short term survival = homeostatic balance

Early mutant cell clones




p53 mutations in UV carcinogenesis !

- UV induced skin cancers show up to 100% p53 mutation rate (54-100%)
- p53 defective cells are less prone to apoptosis induction by UV light
- p53 mutations are present in sun-damaged skin and AKs
- Most loss of function p53 mutations result in increased p53 immunopositivity given accumulation of mutated / dysfunctional p53 protein

Cancer Res. 1993 Jul 1;53(13):2963-4.
Neoplasia. 1999 Nov;1(5):468-75.
Cancer Res. 2007;67:4648-4656.

p53 positive cell clones

- p53 positive cells are otherwise normal appearing and on H&E they are indistinguishable from normal KC
- The cell groups are clonal expansion of a single mutated cell
- These clones, 10–3000 cells in size, are present at frequencies exceeding 40 cells per cm² and together involve as much as 4% of the epidermis




Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9.

p53 positive cell clones are likely earliest detectable precursors of SCC

- The mutation spectra found in epidermal p53 clones resemble that of non-melanoma skin cancer.
- Coexisting AK, CIS and SCC have been found to share similar mutations, further supporting the notion that p53 mutations appear early in the development of skin cancer
- The exact same mutations were not identified in the same geographic locations.
- The p53 clones in normal skin surrounding SCC were significantly more frequent and larger in size than those in skin surrounding BCC or melanocytic nevus, indicating an association between p53 clones and SCC.

Exp Dermatol. 2004 Oct;13(10):649-53.
Oncogene. 1996 Feb 15;12(4):765-73.

p53 cell clones expand with continued UVB exposure



Cancer Res. 2003 Feb 1;63(3):977-83.

p53 clone growth is promoted by UVB

- p53 clones contain p53 UV signature mutations
- In mouse models after p53 clone formation is stopped clones regress.
- Regression also takes place in mice defective in adaptive immunity.

What is the driving force behind UV induced p53 clone expansion?

Cancer Res. 2001 Feb 1;61(3):977-83.
Semin Cancer Biol. 2005 Apr;15(2):97-102.
Cancer Res. 2007;67:4648-4656.

Apoptosis of surrounding normal keratinocytes drives p53 clone expansion

- Survivin is an apoptosis inhibitor
- Keratinocyte overexpression of survivin (decreased apoptosis) increases number of p53 clones but decreases their size and rate of growth.
- UV induced apoptosis of KCs surrounding p53 clones is one of the driving forces of clone expansion
- p53 clones regress with good sun protection

Cancer Res. 2003 Feb 15;63(3):977-83.
Semin Cancer Biol. 2005 Apr;15(2):97-102.
Cancer Res. 2007;67:4699-4696.

Effect of marked genotoxic trauma on p53 clones

- UV-induced ablation of the epidermal basal layer including p53-mutant clones reduces UV induced keratinocyte carcinogenesis



Carcinogenesis (2012) 33 (3):714-720.

Science

Home News Journals Topics Careers
Science Science Advances Science Immunology Science Robotics Science Signaling Science Translational Medicine




SHARE RESEARCH ARTICLE

High burden and pervasive positive selection of somatic mutations in normal human skin

Ilirigoien Martincorena¹, Amit Roshan², Moritz Gerstang¹, Peter Ellis¹, Peter Van Looy^{3,4}, Stuart McLaren¹, David C. Wedge¹, Anthony Fullam¹, Ludmil B. Alexandrov¹, Jose M. Tubio¹, Lucy Stebbings¹, Andrew Menzies¹, Sara Widaa¹, Michael R. Stratton¹, Philip H. Jones^{5,1}, Peter J. Campbell^{1,2}


¹Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK
²MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK
³Francis Crick Institute, London, UK
⁴Department of Human Genetics, University of Leuven, Leuven, Belgium
⁵Department of Haematology, University of Cambridge, Cambridge, UK
Corresponding author. E-mail: phj20@mrc-cu.cam.ac.uk (P.H.J.); pc@sanger.ac.uk (P.J.C.)

Science 22 May 2015
Vol. 348, Issue 6237, pp. 880-886
DOI: 10.1126/science.1266806




Genes significantly mutated in normal human skin

- NOTCH1 (Notch homolog 1)
- FAT1 (Ubiquitin-like protein FAT10)
- NOTCH2 (Notch homolog 2)
- TP53 (tumor protein p53)
- RBM10 (RNA binding protein 10)
- NOTCH3 (Notch homolog 3)



<https://www.sciencenews.org/node/9191217?mode=upick&context=166>


Non-melanoma Skin Cancers



<https://www.sciencenews.org/node/9191217?mode=upick&context=166>

Actinic Keratoses

- AKA solar keratoses or “precancers”
- Precancerous
- If untreated, 0.1% per year turn into SCC
- the average patient at time of diagnosis has 7.7 AKs
- 60% of SCCs develop from AKs
- Risk factors are the same as SCC
- May be prevented with sunscreen and low fat diet



Actinic Keratosis

- Occur on sun-damaged skin of head, neck, upper trunk, extremities
 - Often clusters on ears, upper forehead, nasal bridge, malar eminences, dorsal hands, extensor forearms, and scalp in bald individuals
- Classic appearance:
 - rough or gritty pink to red macule or papule
 - angular borders
 - angular yellow scale



Destructive treatment

- Cryotherapy



Field treatment

- 5-fluorouracil cream
- photodynamic therapy (PDT with ALA or MAL)
- imiquimod
- ingenol mebutate gel 0.05%
- diclofenac 3% gel
- chemical peels



5-fluorouracil treatment effects (2x/day for 30 days)



<http://www.espernet.com/bookof-uday/>



Squamous Cell Carcinoma

- 300,000 per year in US
- Most common skin cancer in AA
- Risk Factors:
 - Cumulative long term exposure to UV light
 - Radiation tx
 - Immunosuppression
 - Renal transplant pts have 253-fold increased risk
 - Lesions appear 2-4 yrs post transplantation
 - Chronic ulceration, scar, HPV, chemical carcinogens

Squamous Cell Carcinoma

- Risk of metastasis
 - 5-year rate of metastasis - 5%
- Risk of recurrence
 - 5-year rate of recurrence - 8%
- Factors affecting risk:
 - Size >2 cm (15% recur, 30% metastasize)
 - High risk locations: lip & ear (10 – 25%)
 - Injured/chronically diseased skin (38%)
 - Perineural invasion (35%)
 - Immunosuppression

SCC variants

- Keratoacanthoma
- SCC in situ: Bowen's disease, Erythroplasia of Queyrat
- Invasive SCC
- Marjolin's Ulcer

SCC variants

- **Keratoacanthoma**
- SCC in situ: Bowen's disease, Erythroplasia of Queyrat
- Invasive SCC
- Marjolin's Ulcer

Keratoacanthoma

- Rapid growth, plateau phase, regression
- Clinically "benign" and spontaneously involutes
 - Currently we are unable to differentiate from well differentiated SCC with potential aggressive phenotype
- Head and neck or sun-exposed extremities
- Solitary



Syndromes with multiple keratoacanthomas

- The Grzybowski type:
 - typically diagnosed in adulthood
 - sudden appearance of hundreds of lesions in a disseminated fashion
 - the lesions are generally 2-3mm in diameter
 - found anywhere on the body:
 - even palms, soles, larynx, and oral mucosa



Syndromes with multiple keratoacanthomas

- The Ferguson-Smith variant:
 - typically first lesions in 2nd or 3rd decade of life
 - multiple self-healing squamous epitheliomas of Ferguson-Smith
 - sun-exposed areas and sites of trauma
 - often multiple lesions at a time
 - red macule – papule - grows rapidly for 2–4 wks
 - 2–3 cm in diameter, stable for up to 2 months
 - involutes and leaves scar
 - can be locally aggressive, metastasis is rare
- Loss-of-function *TGFBR1* mutations
Nat Genet. 2011 Feb 27;43(4):365-9.



SCC variants

- Keratoacanthoma
- **SCC in situ: Bowen's disease, Erythroplasia of Queyrat**
- Invasive SCC
- Marjolin's Ulcer

SCC in situ

- Bowen's disease
- Elderly
- Sun-exposed skin
- De novo or from AKs
- Head & neck >> extremities and trunk
- DDx: AK, sBCC, psoriasis, nummular eczema
- On the penis: Erythroplasia of Queyrat
- If SCC rises from Bowen's increased risk of metastasis (30%)




SCC variants

- Keratoacanthoma
- SCC in situ: Bowen's disease, Erythroplasia of Queyrat
- **Invasive SCC**
- Marjolin's Ulcer

Invasive SCC

- Invasive squamous cell carcinoma
- Elderly
- Sun-exposed skin
- De novo or from AKs
- Head & neck >> extremities and trunk
- DDx: AK, sBCC, warts



SCC variants


- Keratoacanthoma
- SCC in situ: Bowen's disease, Erythroplasia of Queyrat
- Invasive SCC
- **Marjolin's Ulcer**



Treatment

- Depends on risk, location, subtype

Squamous Cell Carcinoma



Skin Cancer in Transplant Patients - Clinical Characteristics

- Skin cancer is most common post-transplant malignancy
- Ranges from minor inconvenience to major morbidity to lethal
- Increased risk of metastasis and death



Population-Based Standard Incidence Ratios of Skin Cancer in transplant Patients

Squamous cell carcinoma	65 –fold increase
SCC of the lip	20 – 38-fold increase
BCC	10-fold-increase
Melanoma	1.2 – 3.4-fold increase
Kaposi sarcoma	84-fold increase

Skin Cancer in Different Types of Transplants

- Cardiac transplants have a 2.9-fold higher risk of SCC compared to renal transplants
 - Cardiac transplant pts older
 - Immunosuppression more intense
- Skin cancer is less common in liver transplants than renal or cardiac

Management of Skin Cancer in Transplant Patients – Basic Principles

- Sun protection
 - Avoid natural or artificial tanning
 - Limit outdoor activities 10 am - 3 pm
 - Broad spectrum (UVA/UVB) sunscreen and lip balm
 - Protective clothing and broad-brimmed hats

Management of Skin Cancer in Transplant Patients – Basic Principles

- Education pre- and post-transplant
- Regular surveillance by dermatologist
- Monthly self skin exam
- Monthly self nodal exam with h/o SCC or melanoma
- Annual complete physical and history focused on metastatic potential

Management of Skin Cancer in Transplant Patients

- Aggressive treatment of AKs
 - Cryotherapy
 - 5-fluorouracil cream
 - Topical retinoids
 - Photodynamic therapy (PDT)
- Chemoprophylaxis
 - Systemic retinoids
 - Capecitabine (Xeloda)
- Reduce and alter immunosuppression
- Because of higher risk of metastasis aggressive management is needed

Basal Cell Carcinoma

- Most common malignant cutaneous neoplasm
- Incidence: 2.8 million in the US (M:F = 2:1)
- Risk Factors:
 - Intermittent, intense sun exposure (20% in pts under 50)
- Distribution: head and neck, sometimes sun-protected




Basal Cell Carcinoma

- No universal classification
- Variants
 - Nodular*
 - Superficial*
 - Morpheaform / Sclerosing *
- Very rarely metastasize (~1/10,000)

* all may be pigmented (morpheaform least likely)


Basal Cell Carcinoma

- Epidermal basal layer epithelial cell differentiation



<http://pulpbits.net/?skin-structure-anatomy-diagrams/epidermis-structure-system/>

BCC histological patterns



Nodular BCCs

- Most common variant
- 60% of all BCCs
- Face
- Raised, glassy/pearly papule or nodule
- Overlying telangiectases
- Large, extend deeply
- Ulceration
- Pigmented

!



Superficial BCC

- Second most common
- 15% of BCC
- Favors the trunk and extremities
- Pink, erythematous macule/thin plaque
- Difficult to differentiate from benign inflammatory lesion/SCC/AK



Morpheaform BCC


- AKA sclerosing or infiltrating
- Locally aggressive subtype
- Flat, slightly atrophic or ill-defined plaque
- May appear scar-like
- Actual size often greater than clinically apparent
- Often a histologic determination







Metastatic basal cell carcinoma !


- Rate 1:3000 – 1: 30,000
- Mostly in cases of longstanding deep disease (>8-9 yrs)
- Male to female ratio 2:1
- Median age of first sign of primary tumor: 45yrs
- Route of metastasis: lymphogenic and hematogenic
- Sites: lymph nodes, lungs, bones



Mohs Surgery !

- Developed in the 1938 by Dr Frederick Mohs, a Wisconsin General Surgeon
- Provides superior margin control, maximal tissue sparing and the highest cure rates
- Drawbacks: time and labor intensive, relatively few Mohs surgeons




Other therapeutic options for advanced BCC

Systemic therapies:
alpha-interferon, capecitabine, retinoids


Small molecular inhibitors

Basal cell carcinoma: beyond surgery and irradiation



Therapeutic options for advanced BCC !

Small molecular inhibitors of PTCH signaling:
LDE-225/Erismodegib
GDC-0449/Vismodegib



JAMA Dermatol. 2013;149(5):607-608. doi: 10.1001/jamadermatol.2013.448

Vismodegib

Multicenter, international, two-cohort,
non-randomized study:
63 locally advanced BCC patients

Response rate: 43%
Complete response: 21%

N Engl J Med 2012; 366:2371-2379 June 7, 2012 DOI: 10.1056/NEJMoa1113713

Vismodegib

Multicenter, international, two-cohort,
non-randomized study:
63 locally advanced BCC patients


Adverse events in 55%:
moderate to mild: 30%
serious adverse events: 25%

N Engl J Med 2012; 366:2371-2379 June 7, 2012 DOI: 10.1056/NEJMoa1113713

Commonly reported adverse events

- Alopecia
- Fatigue
- Muscle spasms
- Dysgeusia / ageusia
- Weight loss
- Nausea
- Decreased appetite
- Diarrhea
- Amenorrhea
- Keratitis
- Electrolyte imbalance and azotemia.

N Engl J Med 2012; 366:2371-2379 June 7, 2012 DOI: 10.1056/NEJMoa1113713




Potential drawbacks

- Unknown long term efficacy and side effects
- Potential development of resistance
- Only free for qualifying patients through Genentech Access Solutions, potential significant expenses


Melanocytes

- Melanocyte origin




Melanin Biosynthesis

Tyrosine → DOPA → DOPAquinone
Both steps are catalyzed by tyrosinase




Melanosome Formation



Melanocortin 1 Receptor


- G-protein-coupled receptor on surface of melanocytes
- Seven transmembrane domain
- αMSH binds MC1R
- Dysfunctional MC1R favors synthesis of pheomelanin



John A. D'Orazio, Stuart Jarrett, Amanda Marsch, James Lagrew and Laura Cleary (2013). Melanoma – Epidemiology, Genetics and Risk Factors, Recent Advances in the Biology, Therapy and Management of Melanoma

Melanocyte function in the epidermis

- Melanocytes load keratinocytes with melanosomes for protection against ultraviolet radiation



Tanning

Fitzpatrick skin types

Skin type	Typical Features	Tanning ability
I	Pale white skin, blue/hazel eyes, blond/red hair	Always burns, does not tan
II	Fair skin, blue eyes	Burns easily, tans poorly
III	Darker white skin	Tans after initial burn
IV	Light brown skin	Burns minimally, tans easily
V	Brown skin	Rarely burns, tans darkly easily
VI	Dark brown or black skin	Never burns, always tans darkly



http://www.melaninbioassay.com/fitzpatrick-tanning

Abnormalities of pigmentation

	<ul style="list-style-type: none"> May fade or disappear in winter and with age 	
Lentigo simplex	<ul style="list-style-type: none"> May be due to sunburn 	<ul style="list-style-type: none"> Pigmented elongated rete ridges Increased melanocytes along basal layer Ink-spot variety (deeply pigmented)
Solar lentigo (1)	<ul style="list-style-type: none"> Scattered small brown lesions on sun-damaged areas 	<ul style="list-style-type: none"> Pigmented elongated & clubbed rete ridges Increased melanocytes along basal layer Solar elastosis
Solar lentigo (2)	<ul style="list-style-type: none"> Large well-defined oval patch on face in mature individuals 	


<http://www.dermnetnz.org/doctors/lesions/melanocytic.html>
DermNet New Zealand Trust

Abnormalities of pigmentation




<http://www.dermnetnz.org/doctors/lesions/melanocytic.html>
DermNet New Zealand Trust


Melanoma pathogenesis



Melanoma pathogenesis




Melanoma incidence



Surveillance, Epidemiology, and End Results Program

SEER Stat Fact Sheets: Melanoma of the Skin



Number of New Cases and Deaths per 100,000: The number of new cases of melanoma of the skin was 21.6 per 100,000 men and women per year. The number of deaths was 2.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2008-2012 cases and deaths.

Lifetime Risk of Developing Cancer: Approximately 2.1 percent of men and women will be diagnosed with melanoma of the skin at some point during their lifetime, based on 2010-2012 data.

Prevalence of This Cancer: In 2012, there were an estimated 996,587 people living with melanoma of the skin in the United States.

<http://seer.cancer.gov/statfacts/html/melan.htm>

Melanoma

- Incidence in Caucasians has tripled in the last 30 years
- Lifetime risk 1:35-75
- Median age of diagnosis is 53
- Most common cancer in women aged 25-29


Melanoma Types

- Superficial Spreading Melanoma
- Nodular Melanoma
- Acral Lentiginous Melanoma
- Lentigo Maligna Melanoma

Superficial spreading melanoma

- Most common type of melanoma
 - 70% of all melanomas
- Between ages of 30 and 50 years
- Can arise *de novo* or in a pre-existing nevus

Superficial Spreading Melanoma



Biologix: Dermatology, Third Edition, 2012, Elsevier

SUPERFICIAL SPREADING MELANOMA

Initial phase (months to years)
 Flat, not palpable
 Color variation slight
 Indistinguishable from other early melanomas

Radial growth phase (months to 10 years)
 Border irregular
 Areas of regression appear with angular notching
 Thick areas appear at about 2.5 cm—herald onset of vertical phase

Vertical growth phase (months to years)
 Numerous patterns, depending on degree of growth and regression
 Tumors palpable
 Plaquelike elevation at border
 Nodules in center
 Areas of ulceration and scaling

0 to 0.6 cm
 Brown, brown-black
 Slight focal blue
 Faint red and white

0.6 to 2.5 cm
 Colors become more pronounced
 Angular notching

Highly regressed area


or

Striking contrast in colors
 Blue-gray
 Blue-black
 Red and white

The diagram shows three stages of melanoma growth: a small flat spot (0-0.6 cm), a larger irregular spot with notching (0.6-2.5 cm), and a large, raised, multi-colored lesion. To the right are three photographs of skin lesions corresponding to these stages.

Superficial spreading melanoma


The image shows three photographs of superficial spreading melanoma. The largest photograph on the left shows a large, irregular, multi-colored lesion with a ruler for scale, indicating its size. The two smaller photographs on the right show different views or stages of similar lesions.

ABCDEs of pigmented lesions 

From: **Early Diagnosis of Cutaneous Melanoma: Revisiting the ABCD Criteria**
 JAMA. 2004;292(22):2771-2776. doi:10.1001/jama.292.22.2771

The ABCDEs for melanoma detection are:

- A is for Asymmetry where one-half of the mole is unlike the other.
- B is for Border where the mole is irregular, scalloped or poorly defined.
- C is for Color which varies from one area to another or has different shades of tan, brown, black and sometimes white, red or blue.
- D is for Diameter of a mole when it is bigger than the size of a pencil eraser.
- E is for Evolving or changing in size, shape or color.



Downloaded from the American Medical Association.

Nodular Melanoma

- Second most common
 - 15-30% of melanomas
- Commonly in 60th decade of life
- No radial growth phase → Rapid growth
- Trunk, head and neck most common
- Male predominance
- Usually thicker and more advanced stage at diagnosis
 - Poorer prognosis



Acral Lentiginous Melanoma

- Uncommon
 - 5 – 10% of all melanomas
- Incidence similar across all racial groups
- 7th decade of life
- Represents disproportionate percentage of melanomas in African Americans (70%) and Asians (40%)
- Palms and soles or in and around the nail apparatus



Lentigo Maligna Melanoma

- Lentigo maligna analogous to the radial growth phase(5-20yrs)
- Lentigo maligna melanoma means invasive growth
- 4-15% of Melanomas
- Sun-damaged skin: face - nose and cheek
- Usually slow growth of large precursor lesion



Melanoma management

- Generous biopsy

Biopsy specimen
Sections cut by pathologist

Section with deepest penetration of tumor; this section used to report Breslow microstage and Clark level

Blanchard: Dermatology, Third Edition, 2011, Elsevier

Treatment

- Wide excision**
- Mohs Surgery
- Sentinel lymph node biopsy
- Staging workup—imaging not recommended under 4mm thickness
- Adjuvant therapy
 - Small molecule pathway inhibitors
 - Immunotherapy
- Close follow up

Breslow depth is key

Breslow microstage

Clark levels 1-5

- Intraepidermal
- In papillary dermis
- Fills papillary dermis
- Reticular dermis
- Enters fat

Tumor pictured—reported by pathologist as:
1. Depth of invasion 3.3 mm
2. Clark level 4

Melanoma thickness and Survival

Breslow Depth	5-Year Survival
< 1mm	95%
< 2 mm	89% (77% if ulcerated)
> 4 mm	67% (45% if ulcerated)

Metastasis = 6-18% depending on site

Tumor status

- Tx: Primary tumor cannot be assessed
- T0: No evidence of primary tumor
- Tis: Melanoma in situ

• T1: < 1.0mm	T1a: no ulceration and mitotic rate < 1/mm ²	T1b: with ulceration or mitotic rate > 1/mm ²
• T2: 1.01 - 2.0mm	T2a: no ulceration	T2b: with ulceration
• T3: 2.01 - 4.0mm	T3a: no ulceration	T3b: with ulceration
• T4: > 4.0mm	T4a: no ulceration	T4b: with ulceration


Blanchard CM et al. J Clin Oncol 27(36): 6199-206, 2009

Staging of localized primary melanoma

	T	N	M
0	Tis	NO	MO
IA	T1a	NO	MO
IB	T1b	NO	MO
IIA	T2a	NO	MO
	T2b	NO	MO
IIB	T3a	NO	MO
	T3b	NO	MO
IIC	T4a	NO	MO
	T4b	NO	MO

Blach CM et al. J Clin Oncol 27(36): 6199-206, 2009


Localized primary melanoma prognosis



Blach CM et al. J Clin Oncol 27(36): 6199-206, 2009

Tumor status predicts node positivity

- Early disease features define risk of distant disease
- **Risk of SLN positivity based on tumor thickness**
 - <1 mm: 5%
 - <0.76 mm: 2.5%
 - ≥0.76 mm: 6.3%
 - 0.76-1.0mm with ≥1/mm² mitotic rate: 10%
 - 1.01-2.0 mm: 12%
 - 2.01-4.0 mm: 28%
 - >4 mm: 44%



http://www.cancer.gov/

Reussens DJP et al. Ann Surg Oncol 2001; 10:569.
 Han D et al. Sentinel Lymph Node Metastases in Thin Melanoma. J Clin Oncol 2011.
 Kozlowski RR et al. J Natl Cancer Inst News 2009; 7:208

Node status

- Nx: Lymph nodes cannot be evaluated
- N0: No evidence of cancer in the lymph nodes
- N1: 1 lymph node
 - N1a: micrometastasis
 - N1b: macrometastasis
- N2: 2 or 3 lymph nodes
 - N2a: micrometastases
 - N2b: macrometastases
 - N2c: in transit or satellite lesions but NO positive lymph nodes
- N3: Any of the following:
 - 4 lymph nodes
 - 2-3 positive lymph nodes that are matted
 - in transit or satellite lesions with any number of positive lymph nodes




Blach CM et al. J Clin Oncol 27(36): 6199-206, 2009

Pathologic staging of locally advanced melanoma

Stage IIIA	TI-4a	N1a	MO
	TI-4a	N2a	MO
Stage IIIB	TI-4b	N1a	MO
	TI-4b	N2a	MO
	TI-4a	N1b	MO
	TI-4a	N2b	MO
Stage IIIC	TI-4a	N2c	MO
	TI-4b	N1b	MO
	TI-4b	N2b	MO
	TI-4b	N2c	MO
	Any T	N3	MO

Melanoma survival based on node status and in stage IIIA - IIIC disease




Blach CM et al. J Clin Oncol 27(36): 6199-206, 2009

Pathologic staging of metastatic melanoma

Stage IV Any T Any N M1

Melanoma survival rates stage I – IV



Blanch CM et al. J Clin Oncol 27(36): 6199-206, 2009

Prognosis in melanoma with distant metastasis

- Site of first metastasis
- Serum lactate dehydrogenase (LDH)
- Number of metastases
- Surgical resectability
- Response to therapy
- Duration of remission



Weide B et al Br J Cancer 107: 422-428, 2012.
Tatkin AA et al J Clin Oncol 27: 38-44, 2009.

Metastasis site

- Mx: metastases cannot be evaluated
- M0: No evidence of metastases
- M1a: sites skin, subcutaneous or distant lymph nodes
- M1b: metastases to lung
- M1c: Metastases to all other visceral sites
Distant metastases to any site + elevated serum LDH

• M1a:	62%
• M1b:	53%
• M1c:	33%

Blanch CM, Gershenwald JE, Soong S, et al. J Clin Oncol 27(36): 6199-206, 2009

Prognostic importance of LDH level


Lactate dehydrogenase (LDH)

- Released after cell damage or death
- Higher tumor burden and progression
- Included in current staging system
- Not specific:
 - Other malignancies, hemolysis, infection, inflammation and ischemic tissue damage
- Negative predictive value for metastatic relapse

	survival	
	1 year	2 year
normal LDH	65%	40%
elevated LDH	32%	18%

Kluger HM et al. Clin Cancer Res (2011) 17(6):2417-25.
Blanch CM et al. J Clin Oncol 27(36): 6199-206, 2009
Solomon et al. Int J Biol Markers (2011) 26(2):82-7.
Vercellino P et al. Dermatol Res Pract (2012) 2012:200543.
Ho et al. Mol Cancer (2012) Oct 9, 11:76.

Stage IV melanoma prognosis



Blanch CM, Gershenwald JE, Soong S, et al. J Clin Oncol 27(36): 6199-206, 2009

Other prognostic factors

- Anatomic site
- Age
- Gender
- Marital status
- Tumor infiltrating lymphocytes and other immunologic markers
- Molecular markers of prognosis**
- Serum markers
- Circulating tumor cells and other tumor cell derived factors
- Clark's level
- Vertical growth phase
- Regression
- Increased tumor vascularity
- Angiotropism
- Lymphovascular invasion
- Neurotropism

Molecular markers of melanoma progression: mRNA signatures

- mRNA based studies:**
 - Winnepeninicka V et al. J Natl Cancer Inst. 2006;98:472-482. 57.
 - Brunner G et al. Cancer Biother Radiopharm. 2008;23:451-459.
 - Gschaider M et al. PLoS One. 2012;7:e49865.
 - Brunner G et al. J Cancer Res. Clin Oncol. 2013;139:249-258.
 - Wardwell-Ozgo J et al. Oncogene. 2014;33:1017-1026.
 - Sivendran S et al. J Invest Dermatol. 2014;134:2202-2211.
 - Gerami P et al. J Am Acad Dermatol. 2015;72:780.e3-785.e3.
 - Gerami P et al. Clin Cancer Res. 2015;21:175-183.
- Very few overlapping genes were identified by the studies**
- Many of even the overlapping signals were likely from not melanocytes**

Weiss SA et al. Cancer. 2015 Dec 1;121(23):4108-23.

Molecular markers of melanoma progression: mRNA signature based clinical prognostic test

- 28 target genes and 3 control genes**, proprietary gene expression profile evaluation
 - FFPE tissue, q-RT-PCR based gene expression analysis**
 - Development dataset (n=107)
 - Training dataset (n=164)
 - Validation dataset (n=104)
 - Predicts risk of nodal metastasis**
- 5-year disease free survival rate in the validation set:
 97% class 1
 31% class 2
- NPV and PPV were 93% and 72%, respectively


Gerami P et al. Clin Cancer Res. 2015;21:175-183.

Molecular markers of melanoma progression: mRNA signature based clinical prognostic test

- 28 target genes and 3 control genes**, proprietary gene expression profile evaluation
 - prognostic accuracy compared with sentinel lymph node biopsy (SLNB) in a multicenter cohort of 217 patients
 - disease-free, distant metastasis-free, and overall survivals:
 - more significant and better predictor of each end point compared to SLNB
 - in combination with SLNB improved prognostication
 - class 2 (high-risk outcome) and a negative SLNB result
- 5-year disease-free (35%), distant metastasis-free (49%), overall survivals (54%)

Gerami P et al. J Am Acad Dermatol. 2015;72:780.e3-785.e3.

Melanoma pathogenesis



Lancet. 2005 Feb 19-25;365(9460):687-701.

ARTICLES


nature
genetics

Exome sequencing identifies recurrent mutations in *NF1* and RASopathy genes in sun-exposed melanomas

Michael Krauthammer^{1,2}, Yong Kong³, Antonella Bacchiocchi⁴, Perry Evans⁴, Natapol Pornputtpong⁵, Cen Wu³, James P McCusker⁷, Shuangge Ma³, Elaine Cheng⁴, Robert Straub⁴, Merdan Serin⁴, Marcus Bosenberg^{2,4}, Stephan Ariyan⁶, Deepak Narayan⁶, Mario Sznoor⁷, Harriet M Kluger⁷, Shrikant Mane^{8,9}, Joseph Schlessinger¹⁰, Richard P Lifton^{9,11} & Ruth Halaban⁴

Exome sequencing identifies recurrent mutations in *NF1* and *RASopathy* genes in sun-exposed melanomas


Michael Krauthammer^{1,2}, Yong Kong³, Antonella Bacchocchi⁴, Perry Evans¹, Natapol Pornputtpong², Cara Wu⁵, James P McCusker², Shuangge Ma², Elaine Cheng¹, Robert Strzamb¹, Merdan Serin¹, Marcus Bosenberg^{2,4}, Stephan Ariyan⁶, Deepak Narayan⁶, Mario Sznol⁷, Harriet M Kluger⁷, Shrikant Mane^{8,9}, Joseph Schlessinger¹⁰, Richard P Lifton^{9,11} & Ruth Halaban¹



- Very high mutation burden in melanoma
- Mutation profile groups (BRAF, RAS, NF1)
- Most of the mutations are present also in melanocytic nevi

BRAF inhibitor treatment in melanoma

- Typical response for patients on BRAF inhibitors. BRAF inhibitor (vemurafenib) can induce PET-CT responses in as little as two weeks



Small molecular inhibitors in melanoma therapy






Figure 2 Schematic diagram representing pleiotropic signaling pathways responsible for resistance to BRAF or MEK inhibitors in melanoma. Inhibitors and pharmacological targets in melanoma are indicated. Inhibitors of the RAS pathway are indicated in red. Inhibitors of the MEK pathway are indicated in green. Inhibitors of the ERK pathway are indicated in blue. Inhibitors of the PI3K pathway are indicated in purple. Inhibitors of the mTOR pathway are indicated in orange. Inhibitors of the JAK/STAT pathway are indicated in yellow. Inhibitors of the Hedgehog pathway are indicated in pink. Inhibitors of the Wnt pathway are indicated in light blue. Inhibitors of the Notch pathway are indicated in light green. Inhibitors of the TGF-β pathway are indicated in light purple. Inhibitors of the TNF pathway are indicated in light orange. Inhibitors of the IL-6 pathway are indicated in light yellow. Inhibitors of the IL-1 pathway are indicated in light pink. Inhibitors of the IL-17 pathway are indicated in light blue. Inhibitors of the IL-22 pathway are indicated in light green. Inhibitors of the IL-23 pathway are indicated in light purple. Inhibitors of the IL-27 pathway are indicated in light orange. Inhibitors of the IL-35 pathway are indicated in light yellow. Inhibitors of the IL-36 pathway are indicated in light pink. Inhibitors of the IL-37 pathway are indicated in light blue. Inhibitors of the IL-38 pathway are indicated in light green. Inhibitors of the IL-39 pathway are indicated in light purple. Inhibitors of the IL-40 pathway are indicated in light orange. Inhibitors of the IL-41 pathway are indicated in light yellow. Inhibitors of the IL-42 pathway are indicated in light pink. Inhibitors of the IL-43 pathway are indicated in light blue. Inhibitors of the IL-44 pathway are indicated in light green. Inhibitors of the IL-45 pathway are indicated in light purple. Inhibitors of the IL-46 pathway are indicated in light orange. Inhibitors of the IL-47 pathway are indicated in light yellow. Inhibitors of the IL-48 pathway are indicated in light pink. Inhibitors of the IL-49 pathway are indicated in light blue. Inhibitors of the IL-50 pathway are indicated in light green. Inhibitors of the IL-51 pathway are indicated in light purple. Inhibitors of the IL-52 pathway are indicated in light orange. Inhibitors of the IL-53 pathway are indicated in light yellow. Inhibitors of the IL-54 pathway are indicated in light pink. Inhibitors of the IL-55 pathway are indicated in light blue. Inhibitors of the IL-56 pathway are indicated in light green. Inhibitors of the IL-57 pathway are indicated in light purple. Inhibitors of the IL-58 pathway are indicated in light orange. Inhibitors of the IL-59 pathway are indicated in light yellow. Inhibitors of the IL-60 pathway are indicated in light pink. Inhibitors of the IL-61 pathway are indicated in light blue. Inhibitors of the IL-62 pathway are indicated in light green. Inhibitors of the IL-63 pathway are indicated in light purple. Inhibitors of the IL-64 pathway are indicated in light orange. Inhibitors of the IL-65 pathway are indicated in light yellow. Inhibitors of the IL-66 pathway are indicated in light pink. Inhibitors of the IL-67 pathway are indicated in light blue. Inhibitors of the IL-68 pathway are indicated in light green. Inhibitors of the IL-69 pathway are indicated in light purple. Inhibitors of the IL-70 pathway are indicated in light orange. Inhibitors of the IL-71 pathway are indicated in light yellow. Inhibitors of the IL-72 pathway are indicated in light pink. Inhibitors of the IL-73 pathway are indicated in light blue. Inhibitors of the IL-74 pathway are indicated in light green. Inhibitors of the IL-75 pathway are indicated in light purple. Inhibitors of the IL-76 pathway are indicated in light orange. Inhibitors of the IL-77 pathway are indicated in light yellow. Inhibitors of the IL-78 pathway are indicated in light pink. Inhibitors of the IL-79 pathway are indicated in light blue. Inhibitors of the IL-80 pathway are indicated in light green. Inhibitors of the IL-81 pathway are indicated in light purple. Inhibitors of the IL-82 pathway are indicated in light orange. Inhibitors of the IL-83 pathway are indicated in light yellow. Inhibitors of the IL-84 pathway are indicated in light pink. Inhibitors of the IL-85 pathway are indicated in light blue. Inhibitors of the IL-86 pathway are indicated in light green. Inhibitors of the IL-87 pathway are indicated in light purple. Inhibitors of the IL-88 pathway are indicated in light orange. Inhibitors of the IL-89 pathway are indicated in light yellow. Inhibitors of the IL-90 pathway are indicated in light pink. Inhibitors of the IL-91 pathway are indicated in light blue. Inhibitors of the IL-92 pathway are indicated in light green. Inhibitors of the IL-93 pathway are indicated in light purple. Inhibitors of the IL-94 pathway are indicated in light orange. Inhibitors of the IL-95 pathway are indicated in light yellow. Inhibitors of the IL-96 pathway are indicated in light pink. Inhibitors of the IL-97 pathway are indicated in light blue. Inhibitors of the IL-98 pathway are indicated in light green. Inhibitors of the IL-99 pathway are indicated in light purple. Inhibitors of the IL-100 pathway are indicated in light orange.

Immune checkpoint blockade for melanoma therapy



Hope for the future in melanoma therapy



<http://medRxiv.org/content/2015-04-highlights-potential-cancer-immunotherapy-therapy.html>

Summary: Cutaneous malignancies

- Skin: barrier
- UV radiation: most important epidermal carcinogen
- Precancerous lesions: Actinic keratosis
- Most common skin cancers
 - Non melanoma skin cancers:
 - Basal cell carcinoma
 - Squamous cell carcinoma
 - Melanoma

Questions

- Email: Gyorgy.Paragh@roswellpark.org